ID   KP-N-NY
AC   CVCL_Y135
SY   Kyoto Pediatrics-Neuroblastoma-NY
DR   CGH-DB; 67-1
DR   CGH-DB; 9088-4
DR   Wikidata; Q54900390
RX   CelloPub=CLPUB00582;
RX   PubMed=12702577;
RX   PubMed=23268333;
CC   Population: Japanese.
CC   Derived from site: In situ; Adrenal gland; UBERON=UBERON_0002369.
DI   NCIt; C4827; Adrenal gland neuroblastoma
DI   ORDO; Orphanet_635; Neuroblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
AG   5Y
CA   Cancer cell line
DT   Created: 07-11-14; Last updated: 29-06-23; Version: 6
//
RX   CelloPub=CLPUB00582;
RA   Sugimoto T., Kuroda H., Yagyu S., Gotoh T., Osone S., Tamura S.,
RA   Iehara T., Hosoi H.;
RT   "Cellular and molecular characteristics of established neuroblastoma
RT   cell lines.";
RL   J. Cancer Res. Therap. Oncol. 7:201.1-201.15(2019).
//
RX   PubMed=12702577;
RA   Saito-Ohara F., Imoto I., Inoue J., Hosoi H., Nakagawara A.,
RA   Sugimoto T., Inazawa J.;
RT   "PPM1D is a potential target for 17q gain in neuroblastoma.";
RL   Cancer Res. 63:1876-1883(2003).
//
RX   PubMed=23268333; DOI=10.1016/j.canlet.2012.12.011;
RA   Sugimoto T., Gotoh T., Yagyu S., Kuroda H., Iehara T., Hosoi H.,
RA   Ohta S., Ohira M., Nakagawara A.;
RT   "A MYCN-amplified cell line derived from a long-term event-free
RT   survivor among our sixteen established neuroblastoma cell lines.";
RL   Cancer Lett. 331:115-121(2013).
//